SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Why Queen Kitty ($QKitty) Is The Meme Token You’ve Been Waiting For  Queen Kitty isn’t just another hype project—this is a real movement with substance and community power!  Why hold $QKitty? 😼 Real dev, real builds: No fake teams, no copy-paste code. Everything you see is made from scratch. 💧 Working Faucet: Free QKitty for the community. Want to know how? Just ask! 🏆 Big Buy Competition Bot: See top buyers live, fight for the throne, and win rewards! 🎮 Multi-token P2E game coming soon: Play and earn across Web, iOS, Android! 🐾 NFT collecting soon: Cutest collection in crypto, bringing perks and more ways to earn.  Queen Kitty means innovation, transparency, and real delivery for holders. Curious? Join the chat and ask anything!  $QKitty: By the community, for the community. To the moon, together! 🚀🐱

Queen Kitty

Queen Kitty ($QKITTY) is trending as the community discusses its trading bot, which some users claim generates daily interest. Chatter also mentions upcoming developments like a DEX and swap feature. Some users are reporting losses, while others express bullish sentiment, referring to potential gains.

Trump For President

The Trump Crypto coin is trending amidst mixed sentiment, with some users expressing frustration and others hoping for a turnaround. Community members are discussing the coin's performance, potential links to political figures, and comparing it to other crypto assets. Some traders are speculating on potential upside.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is trending as community members express strong conviction in the project's long-term potential within the Solana ecosystem. Discussions highlight its reflexive liquidity model and its potential for significant growth, with many seeing it as more than just a meme coin. Some users are suggesting now is an opportune time to invest.

Shibmas was launched on the 9th Of December. The project is a meme token and gives homage to Shiba Inu the token. The token is a playful character who is bringing the Christmas spirit to token holders all around the world. We plan on getting many listings on various exchanges in the coming days. We have over 1000 holders in 24 hours and we aim on getting over 10000 holders within the next week and in the run up to Christmas

Shibmas

Shibmas ($SMAS) is trending, with community members highlighting its potential for a breakout and low market cap. Traders are closely watching key levels and volume, noting positive chart structure and momentum, while also pointing to its availability on Phantom Wallet and association with other meme coins.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as community members discuss its potential to break $200 and reach new highs, with some eyeing a move towards $250. Sentiment around Solana is positive, as many allude to the "WAGMI" (We're All Gonna Make It) mentality. Mentions of potential Solana ETFs are circulating, as well as other Solana-based tokens such as SMAS and WAGMI.

WorldFinancial

$WLFI is trending amidst community discussions around its association with $TRUMP and potential for 'generational wealth.' Some speculate on its regulatory compliance benefits and tokenization of real-world assets, while others express skepticism, citing centralization and lack of utility; the community is split between bullish excitement and bearish concern.

STMicroelectronics NV is a global semiconductor company, which engages in the business of designing, developing, manufacturing, and marketing products used in a wide variety of applications for automotive, industrial, personal electronics and communications equipment, computers, and peripherals. It operates through the following segments: Automotive and Discrete Group (ADG), Analog, MEMS, and Sensors Group (AMS), Microcontrollers and Digital ICs Group (MDG), and Others. The ADG segment includes dedicated automotive integrated circuits and discrete and power transistor products. The AMS segment offers analog, smart power, MEMS sensors and actuators, and optical sensing solutions. The MDG segment focuses on general-purpose microcontrollers and microprocessors, connected security products, memories, and RF and communications products. The Others segment is involved in sales assembly services and other revenues. The company was founded in June 1987 and is headquartered in Plan-Les-Ouates, Switzerland.

ST Microelectronics - New York Shares

STMicroelectronics NV

STMicroelectronics is trending due to a series of analyst ratings and price target adjustments, sparking discussions around the stock's valuation. Community members are weighing the significance of these expert opinions against the backdrop of the company's initiatives in AI, silicon photonics, and chip manufacturing technology. Investors are also monitoring partnerships and buyback programs.

Baby Doge Coin is a meme cryptocurrency designed to be deflationary and more scarce over time. All holders of Baby Doge will earn more baby doge that is automatically sent to your wallet by simply holding Baby Doge coins in your wallet. Watch the amount of baby doge grow in your wallet as baby doge coin holders automatically receive a 5% fee from every on chain transaction that happens on the Baby Doge ecosystem. The community receives more baby doge coins from the fees generated each transaction.

Baby Doge Coin

Baby Doge Coin is trending as the community speculates on potential exchange listings and reflects on recent price movement. Some are discussing the possibility of deleting zeros from the price and drawing comparisons to similar meme coin rallies. Community members are actively sharing price predictions and discussing accumulation strategies.

Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.

Avidity Biosciences Inc

Avidity Biosciences ($RNA) is trending amid rumors of a potential acquisition by Novartis, which has sparked significant discussion among investors. The community is focused on the potential buyout price and what this may mean for other companies in the RNA therapeutics space. Community members point to strong financials and potential for continued growth and have fueled speculation around other potential suitors.

Just a dead guy

DEADGUY CRYPTO is trending as the community buzzes about its potential, particularly its market cap and possible rise relative to competitors, with some highlighting its position on Phantom Wallet. Many users are sharing the contract address and encouraging others to buy, citing the coin's holder count and potential for substantial returns as a reason for its current momentum.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Ligand Pharmaceuticals and Pelthos Therapeutics rose on Thursday after the commercial launch of Zelsuvmi (berdazimer) topical gel, developed under their partnership,&nbsp;to treat a common viral skin infection.<a href="https://stocktwits.com/symbol/PTHS">Pelthos Therapeutics</a> surged 60.8% to close at $10.01 on Thursday, while&nbsp;<a href="https://stocktwits.com/symbol/LGND">Ligand Pharmaceuticals</a> gained 2.1%.The launch triggered a $5 million milestone payment to Ligand under the companies’ license agreement. Under the terms of the licensing deal, Ligand is also entitled to a 13% royalty on worldwide sales of Zelsuvmi and up to $5 million in additional commercial milestones.Ligand also holds a 56% equity stake in Pelthos following the completion of a merger between Pelthos and Channel Therapeutics on July 2.Pelthos announced the merger earlier this month, in which CHRO Merger Sub, a wholly owned subsidiary of Channel, merged with LNHC, a wholly owned subsidiary of Ligand.&nbsp;LNHC survived as a subsidiary of Channel, and the combined company is now operating under the Pelthos Therapeutics name. Concurrent with the merger, Pelthos raised $50.1 million in a private placement led by Murchinson.&nbsp;The investment included new equity as well as the cancellation of $18.8 million in previously advanced bridge capital used to support the commercial launch of Zelsuvmi.Zelsuvmi is a nitric oxide-releasing topical gel approved by the U.S. Food and Drug Administration in 2024 for the treatment of molluscum contagiosum,&nbsp;sometimes known commonly as “water warts”, in patients aged one year and older.&nbsp;It is the first prescription medication approved for at-home application by patients, parents, or caregivers. The product was developed using the nitric oxide-based Nitricil platform, now owned by Ligand.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.On Stocktwits, retail sentiment for both Ligand Pharmaceuticals and Pelthos Therapeutics was ‘bullish’, with ‘high’ message volume for Ligand and ‘extremely high’ activity for Pelthos.Ligand’s stock has gained 15.3%so far in 2025, while Pelthos has surged 266.3% over the same period.See also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-threatens-canada-with-35-tariff-by-august-mulls-blanket-rates-for-others/ch8TD9uR5l4">Trump Threatens Canada With 35% Tariff By August, Mulls Blanket 15-20% Rates For Other Countries</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ligand Pharmaceuticals (LGND) and Pelthos Therapeutics (PTHS) commercially launched Zelsuvmi (berdazimer) topical gel (Photo credit: Getty Images)

Pelthos, Ligand Gain After Launch Of First Prescription-At-Home Treatment For Water Warts

The launch triggered a $5 million milestone payment to Ligand, which also holds a 56% stake in Pelthos and is eligible for royalties and additional commercial milestones.

Equity

Shares of Channel Therapeutics Corporation (CHRO) rocketed 61% on Thursday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investor.ligand.com/news-and-events/press-releases/news-details/2025/Ligand-Subsidiary-Pelthos-Therapeutics-to-Combine-with-Channel-Therapeutics/default.aspx">entered</a> into a definitive merger agreement with biopharmaceutical firm Ligand Pharmaceuticals Incorporated (LGND).Under the agreement, Ligand’s wholly owned subsidiaries, Pelthos Therapeutics Inc. and LNHC, Inc., will combine with CHRO Merger Sub Inc., a wholly-owned subsidiary of Channel.Channel will acquire 100% of the issued and outstanding equity interests of Pelthos Therapeutics and LNHC, and will change its name to Pelthos Therapeutics Inc.Ligand has agreed to invest $18 million in the combined company, while a group of strategic investors led by Murchinson has agreed to invest $32 million.The transaction is expected to close in the summer of 2025.Once the transaction is completed, the combined company will trade on the NYSE American exchange under the ticker PTHS.Channel, a non-opioid pain treatment therapeutics provider, stated that the combined company will initially focus on accelerating the commercialization of Pelthos’ FDA-approved Zelsuvmi topical gel for the treatment of Molluscum contagiosum infections in adults and pediatric patients aged one year and older.Molluscum contagiosum is a poxvirus, afflicting an estimated 16.7 million people in the United States.Ligand will be entitled to a 13% royalty on worldwide sales of Zelsuvmi, the company said.The combined company will also retain Channel’s existing development programs for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks, it added.Channel CEO Frank Knuettel II said that the company performed “extensive due diligence” on the Zelsuvmi market opportunity.“Strategically, it (the merger) provides the potential for near-term revenue generation from an FDA-approved drug, the opportunity to advance Channel’s existing NaV 1.7 programs, and expanded capitalization from strong, long-standing investors,” he said.“This transaction presents a compelling opportunity to launch a commercial-ready product, with significant financial backing from Murchinson, that has the potential to deliver both near and long-term value to our shareholders,” said Ligand CEO Todd Davis.On Stocktwits, retail sentiment around Ligand jumped further into the ‘extremely bullish’ territory over the past 24 hours coupled with a surge in message volume from ‘low’ to ‘extremely high’<figure class="image"><img style="aspect-ratio:648/147;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_17_at_10_29_08_AM_png_52226d4e3f.webp" alt="LGND's Sentiment Meter and Message Volume as of 10:30 a.m. ET on April 17, 2025 | Source: Stocktwits" width="648" height="147"><figcaption>LGND's Sentiment Meter and Message Volume as of 10:30 a.m. ET on April 17, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/LGND">LGND stock</a> is down by about 3% this year but up by over 33% over the past 12 months.Retail sentiment around Channel, meanwhile, jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours.<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2025_04_17_at_10_29_44_AM_png_bccf41e1ea.webp" alt="CHRO's Sentiment Meter and Message Volume as of 10:30 a.m. ET on April 17, 2025 | Source: Stocktwits"><figcaption>CHRO's Sentiment Meter and Message Volume as of 10:30 a.m. ET on April 17, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/CHRO">CHRO stock</a> is up by about 172% year-to-date but down by nearly 1.5% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/lockheed-martin-stock-drops-after-cfo-jay-malave-steps-down-just-days-before-q1-earnings/chQEM9RRbfN">Lockheed Martin Stock Drops After CFO Jay Malave Steps Down Just Days Before Q1 Earnings</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

Channel Therapeutics Stock Soars On Announcement Of Subsidiary’s Merger With Ligand Pharma Units: Retail’s Elated

Under the agreement, Ligand’s wholly owned subsidiaries, Pelthos Therapeutics Inc. and LNHC, Inc. will combine with CHRO Merger Sub Inc., a wholly-owned subsidiary of Channel.

Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report fourth quarter and full year 2024 financial results before the opening of the U.S. financial markets on...

Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will present at the Oppenheimer 35th Annual...

Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) will host its Investor and Analyst Day in Boston today. The event will feature presentations from Ligand CEO Todd Davis, CFO Tavo Espinoza, and...

Ligand to Present at Stifel 2024 Healthcare Conference

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will present at the Stifel 2024 Healthcare...

Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and nine months ended September 30, 2024, and provided an operating forecast and business update...

Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will host an Investor and Analyst Day in Boston on Tuesday, December 10, 2024 from 10:30 a.m. to 12:00 p.m. Eastern Time...

Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report third quarter 2024 financial results before the opening of the U.S. financial markets on Thursday, November 7...

Critical Insights From Ligand Pharmaceuticals Analyst Ratings: What You Need To Know

Latest Ratings for LGND
 DateFirmActionFromTo Feb 2022BenchmarkMaintainsBuy Feb 2022BarclaysMaintainsOverweight Sep 2021BarclaysMaintainsOverweight
 View More Analyst Ratings for LGND...

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.

Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest LGND News

LGNDLigand Pharmaceuticals, Inc. - Ordinary Shares - Class B